Food and Drug Administration approved Wegovy for chronic weight management, but semaglutide, the active ingredient in Ozempic and similar drugs, goes back much further
Inclusion criteria required patients aged 18 years or older with type 2 diabetes mellitus (T2DM), with A1c values less than 10%, and at least one cardiovascular risk factor (CVRF) including hyperlipidemia, essential hypertension, overweight or obesity, and/or chronic ischemic heart disease
Access to new weight loss prescriptions in the UK varies considerably depending on whether treatment is sought through the NHS or via private healthcare
These prices do not include required supplies
According to SkinnyRx's published provider guides, common mild side effects include nausea, constipation, bloating, burping, headache, and fatigue